TENSHA THERAPEUTICS
Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders. The companyรขโฌลธs programs are based on the discovery from the laboratory of Dr. James Bradner at Dana-Farber Cancer Institute of first-in-class, potent small molecule BET bromodomain inhibitors. The companyรขโฌลธs lead program is aimed at the treatment of patients with BRD4-NUT midline carcinoma, acute myeloid leukemias, multiple myeloma, and other diseases. Tensha is a Focused Company funded by HealthCare Ventures.
TENSHA THERAPEUTICS
Industry:
Biotechnology Genetics Health Care Pharmaceutical
Founded:
2011-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.tenshatherapeutics.com
Total Employee:
10001+
Status:
Active
Contact:
+41 61 688 11 11
Email Addresses:
[email protected]
Total Funding:
15 M USD
Technology used in webpage:
SPF Safenames
Similar Organizations
Cullinan Pearl
Cullinan Pearl develops an orally available tyrosine kinase inhibitor to target Epidermal Growth Factor Receptor exon 20 mutations.
GIRx
GIRx is developing small molecule agents to treat diabetes, obesity and other metabolic conditions.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Employees Featured
Founder
Investors List
Torrey Pines Investment
Torrey Pines Investment investment in Funding Round - Tensha Therapeutics
HealthCare Ventures
HealthCare Ventures investment in Series A - Tensha Therapeutics
Official Site Inspections
http://www.tenshatherapeutics.com
- Host name: redirect.idp365.net
- IP address: 217.19.248.132
- Location: Milton Keynes United Kingdom
- Latitude: 52.0675
- Longitude: -0.7569
- Timezone: Europe/London
- Postal: MK14
More informations about "Tensha Therapeutics"
Tensha Therapeutics - Crunchbase Company Profile & Funding
Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders. The โฆSee details»
Tensha Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Tensha Therapeutics, Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
Tensha Therapeutics Inc - Company Profile and News
Company profile page for Tensha Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
Tensha Therapeutics To Be Acquired By Roche - Business Wire
Jan 11, 2016 For more information on Tensha, visit www.tenshatherapeutics.com. Contacts Tensha Therapeutics Douglas E. Onsi, 617-218-1116 President & CEO, Tensha Therapeutics โฆSee details»
Tensha Therapeutics - Products, Competitors, Financials, โฆ
Tensha Therapeutics is a biotechnology company developing small molecule bromodomain inhibitors to regulate disease-linked gene transcription. Tensha noted that its lead preclinical โฆSee details»
Tensha Therapeutics - Company Profile - Tracxn
Feb 11, 2025 Tensha Therapeutics. has raised a total funding of $15M over 1 round. What are the most recent funding rounds of Tensha Therapeutics? Its latest funding round was a Series โฆSee details»
Tensha Therapeutics, Inc. - Drug pipelines, Patents, Clinical
Explore Tensha Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 3 news, Drug:JQ-1.See details»
Tensha Therapeutics, Inc. Overview | SignalHire Company Profile
The position of the CEO is occupied by Douglas E. Onsi. Its headquarters is located at Cambridge, Massachusetts, USA. The number of employees ranges from 1 to 25. The Tensha โฆSee details»
Tensha Therapeutics, Inc.:Company Profile & Technical Research ...
Tensha Therapeutics, Inc. is a company that provides Bromodomain, Small molecule, Enzyme and more. Tensha Therapeutics, Inc. is headquartered in United States Massachusetts. โฆSee details»
TENSHA THERAPEUTICS INC Cambridge MA, 02142 - Company โฆ
Free Business profile for TENSHA THERAPEUTICS INC at 55 Cambridge Pkwy, Cambridge, MA, 02142-1271, US. TENSHA THERAPEUTICS INC specializes in: Commercial Physical and โฆSee details»
Tensha Therapeutics 2025 Company Profile: Valuation, Investors ...
Tensha Therapeutics was founded in 2011. Where is Tensha Therapeutics headquartered? Tensha Therapeutics is headquartered in Cambridge, MA. What industry is Tensha โฆSee details»
Tensha Therapeutics To Be Acquired By Roche - hcven.com
1/2 For Immediate Release Tensha Therapeutics To Be Acquired By Roche โข Lead molecule, TEN-010, in clinical development in cancer โข TEN-010 arising from pioneering work by Dr. โฆSee details»
Roche Takes a $535 Million Chance on Cambridgeโs Tensha โฆ
Jan 11, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tensha Therapeutics, a privately-held company based in Cambridge, MA, announced today it will be acquired by Roche.Founded by โฆSee details»
Tensha Therapeutics : To Be Acquired By Roche - 2016-01-11
Jan 11, 2016 Tensha Therapeutics, a privately-held company based in Cambridge, MA, announced today it will be acquired by Roche. Founded by James E. Bradner, MD, of the โฆSee details»
Tensha Therapeutics - Ownership and Business Overview - Mergr
Tensha Therapeutics, Inc. is a developer of small molecule bromodomain inhibitors to treat cancer and other serious disorders. Company Summary. SECTOR. Life Science. Investor History; โฆSee details»
Tensha Therapeutics - VentureRadar
Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders. The โฆSee details»
Tensha Therapeutics To Be Acquired By Roche - Pipelinereview
Jan 11, 2016 About Tensha Therapeutics Tensha was founded based on discoveries from the laboratory of Dr. James E. Bradner at the Dana-Farber Cancer Institute. Tensha has been โฆSee details»
Roche Acquires Tensha Therapeutics for $115M Upfront
Jan 11, 2016 Roche will acquire Tensha Therapeutics for an upfront cash payment of $115 million, plus additional contingent payments of up to $420 million. Tensha, which was founded โฆSee details»
Tensha Therapeutics to be Acquired by Roche - Technology โฆ
Jan 12, 2016 Founded by James E. Bradner, MD, formerly of the Dana-Farber Cancer Institute, and managed and funded by HealthCare Ventures, Tensha has developed a pioneering โฆSee details»
Tensha Therapeutics - Nature Biotechnology
Apr 10, 2012 Tensha's scientific focus stems from the academic research of James (Jay) Bradner at the Dana-Farber Cancer Institute in Boston. Bradner's laboratory is broadly โฆSee details»